CHADS2: Difference between revisions

From Citizendium
Jump to navigation Jump to search
imported>Robert Badgett
No edit summary
 
imported>Joe Quick
m (subpages)
Line 1: Line 1:
{{subpages}}
'''CHADS2''' is a scoring system for patients with [[atrial fibrillation]] to try and determine their risk of [[stroke]],<ref name="pmid11401607">{{cite journal | journal=JAMA | year=2001 | volume=285 | issue=22 | pages=2864&ndash;70 | title=Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation | author=Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. | id=PMID 11401607 | url=http://jama.ama-assn.org/cgi/content/full/285/22/2864}}</ref> and therefore decide who should receive anticoagulation and who should not.<ref name="pmid15477396 ">{{cite journal | title=Selecting patients with atrial fibrillation for anticoagulation: stroke risk stratification in patients taking aspirin | journal=Circulation | year=2004 | volume=110 | issue=16 | pages=2287&ndash;92 | author=Gage BF, van Walraven C, Pearce L, ''et al.'' | id=PMID 15477396 | doi=10.1161/01.CIR.0000145172.55640.93 | url=http://circ.ahajournals.org/cgi/content/full/110/16/2287}}</ref>
'''CHADS2''' is a scoring system for patients with [[atrial fibrillation]] to try and determine their risk of [[stroke]],<ref name="pmid11401607">{{cite journal | journal=JAMA | year=2001 | volume=285 | issue=22 | pages=2864&ndash;70 | title=Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation | author=Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. | id=PMID 11401607 | url=http://jama.ama-assn.org/cgi/content/full/285/22/2864}}</ref> and therefore decide who should receive anticoagulation and who should not.<ref name="pmid15477396 ">{{cite journal | title=Selecting patients with atrial fibrillation for anticoagulation: stroke risk stratification in patients taking aspirin | journal=Circulation | year=2004 | volume=110 | issue=16 | pages=2287&ndash;92 | author=Gage BF, van Walraven C, Pearce L, ''et al.'' | id=PMID 15477396 | doi=10.1161/01.CIR.0000145172.55640.93 | url=http://circ.ahajournals.org/cgi/content/full/110/16/2287}}</ref>


Line 29: Line 30:
==References==
==References==
<references/>
<references/>
[[Category:CZ Live]] [[Category:Health Sciences Workgroup]]

Revision as of 23:34, 20 November 2007

This article is developing and not approved.
Main Article
Discussion
Related Articles  [?]
Bibliography  [?]
External Links  [?]
Citable Version  [?]
 
This editable Main Article is under development and subject to a disclaimer.

CHADS2 is a scoring system for patients with atrial fibrillation to try and determine their risk of stroke,[1] and therefore decide who should receive anticoagulation and who should not.[2]

It is an easily applied scoring system and each item scores one point (except for stroke, hence the 2)

giving a maximum score of 6.

The risk of stroke as a percentage per year is:

  • 0—1.9%
  • 1—2.8%
  • 2—4.0%
  • 3—5.9%
  • 4—8.5%
  • 5—12.5%
  • 6—18.2%

As detailed in the respective JAMA and Circulation articles, a score of 0 is classified as low risk; 1-2, moderate risk; 3 or more, high risk. Based on this classification, the following treatment strategies were proposed by the authors:

  • 0—Aspirin (325 mg/day most likely to offer benefit, although lower doses may be similarly efficacious)
  • 1 to 2—Aspirin or Warfarin to INR 2.0-3.0, depending on factors such as patient preference
  • 3 or more—Warfarin to INR 2.0-3.0 unless contraindicated (e.g., history of falls, clinically significant GI bleeding, inability to obtain regular INR screening)


The main criticism of the CHADS2 scoring system is that someone with atrial fibrillation and a previous history of stroke, but no other risk factors, is only classified as moderate risk, whereas that person is in fact at high risk of another stroke.

References